Email this article 
Treatment of primary central nervous system lymphomas
- Authors: Cherkashina I.V.1, Vernyuk M.A.1, Chervontseva A.M.1, Gushchina E.E.1, Khayrullina L.S.1, Lunin V.V.1, Zeynalova P.A.2, Fedenko A.A.1
-
Affiliations:
- Р.A. Hertzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center, Ministry of Health of Russia
- Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
- Issue: Vol 16, No 2 (2021)
- Pages: 10-20
- Section: HEMATOLOGIC MALIGNANCIES: TREATMENT
- Published: 03.06.2021
- URL: https://oncohematology.abvpress.ru/ongm/article/view/470
- DOI: https://doi.org/10.17650/1818-8346-2021-16-2-10-20
- ID: 470
Cite item
Full Text
Abstract
Primary lymphoma of the central nervous system (PLCNS) is a rare form of extranodal lymphoma characterized by an aggressive course. In recent decades, the treatment of this disease has undergone significant changes. Modern treatment of PLCNS consists of two steps – induction and consolidation of remission. Improved overall survival of PLCNS patients was achieved through the use of combined immunochemotherapy regimens with high doses of methotrexate and/or cytarabine, which are currently the standard of induction therapy. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation at the consolidation stage provides the most complete elimination of the residual tumor clone. The most effective modes of conditioning are those with the inclusion of tiotepa. In elderly and comorbid patients who are not candidates for autologous hematopoietic stem cell transplantation, promising results were obtained while using maintenance therapy with procarbazine or temozolomide, and further researches will allow us to study the effectiveness of monocolonal anti-CD20 antibodies – rituximab and obinutuzumab.
Treatment options for patients with relapses and / or refractory forms of PLCNS are limited. Certain successes were obtained with the use of new drugs – ibrutinib, nivolumab, lenalidomide, obinutuzumab.
About the authors
I. V. Cherkashina
Р.A. Hertzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Author for correspondence.
Email: laivcher@gmail.com
ORCID iD: 0000-0001-7096-4700
2nd Botkinskiy Proezd, Moscow 125284
Russian FederationM. A. Vernyuk
Р.A. Hertzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center, Ministry of Health of Russia
ORCID iD: 0000-0003-1497-2436
2nd Botkinskiy Proezd, Moscow 125284
Russian FederationA. M. Chervontseva
Р.A. Hertzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center, Ministry of Health of Russia
ORCID iD: 0000-0002-8498-6289
2nd Botkinskiy Proezd, Moscow 125284
Russian FederationE. E. Gushchina
Р.A. Hertzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center, Ministry of Health of Russia
ORCID iD: 0000-0002-5625-3635
2nd Botkinskiy Proezd, Moscow 125284
Russian FederationL. S. Khayrullina
Р.A. Hertzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center, Ministry of Health of Russia
ORCID iD: 0000-0001-8520-0711
2nd Botkinskiy Proezd, Moscow 125284
Russian FederationV. V. Lunin
Р.A. Hertzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center, Ministry of Health of Russia
2nd Botkinskiy Proezd, Moscow 125284
Russian FederationP. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
ORCID iD: 0000-0003-1564-424X
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationA. A. Fedenko
Р.A. Hertzen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Center, Ministry of Health of Russia
ORCID iD: 0000-0003-4927-5585
2nd Botkinskiy Proezd, Moscow 125284
Russian FederationReferences
Supplementary files
